309 related articles for article (PubMed ID: 9862706)
1. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells.
Wahlsten JL; Mills CD; Ramakrishnan S
J Immunol; 1998 Dec; 161(12):6761-7. PubMed ID: 9862706
[TBL] [Abstract][Full Text] [Related]
2. Separation of function between the domains of toxic shock syndrome toxin-1.
Wahlsten JL; Ramakrishnan S
J Immunol; 1998 Jan; 160(2):854-9. PubMed ID: 9551921
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vbeta specificity.
Newton DW; Dohlsten M; Olsson C; Segrén S; Lundin KE; Lando PA; Kalland T; Kotb M
J Immunol; 1996 Nov; 157(9):3988-94. PubMed ID: 8892632
[TBL] [Abstract][Full Text] [Related]
4. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
[TBL] [Abstract][Full Text] [Related]
5. Dissection of the function of HLA class II and costimulation in B cell-mediated and toxic shock syndrome toxin-1-induced T cell proliferation.
Dennig D; O'Reilly RJ
J Immunol; 1993 Jun; 150(12):5231-40. PubMed ID: 7685791
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
[TBL] [Abstract][Full Text] [Related]
7. The alpha 1 domain of the HLA-DR molecule is essential for high-affinity binding of the toxic shock syndrome toxin-1.
Karp DR; Teletski CL; Scholl P; Geha R; Long EO
Nature; 1990 Aug; 346(6283):474-6. PubMed ID: 2377209
[TBL] [Abstract][Full Text] [Related]
8. Activation of murine T cells by toxic shock syndrome toxin-1. The toxin-binding structures expressed on murine accessory cells are MHC class II molecules.
Uchiyama T; Tadakuma T; Imanishi K; Araake M; Saito S; Yan XJ; Fujikawa H; Igarashi H; Yamaura N
J Immunol; 1989 Nov; 143(10):3175-82. PubMed ID: 2509554
[TBL] [Abstract][Full Text] [Related]
9. Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation.
Tiedemann RE; Fraser JD
J Immunol; 1996 Nov; 157(9):3958-66. PubMed ID: 8892628
[TBL] [Abstract][Full Text] [Related]
10. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation.
Arad G; Levy R; Hillman D; Kaempfer R
Nat Med; 2000 Apr; 6(4):414-21. PubMed ID: 10742148
[TBL] [Abstract][Full Text] [Related]
11. Identification of binding domains on the superantigen, toxic shock syndrome-1, for class II MHC molecules.
Soos JM; Russell JK; Jarpe MA; Pontzer CH; Johnson HM
Biochem Biophys Res Commun; 1993 Mar; 191(3):1211-7. PubMed ID: 8466498
[TBL] [Abstract][Full Text] [Related]
12. Staphylococcal cell membrane antigen, a possible antigen in post-methicillin resistant Staphylococcus aureus (MRSA) infection nephritis and IgA nephropathy, exhibits high immunogenic activity that is enhanced by superantigen.
Shimizu Y; Sakurai H; Hirayama K; Seki M; Yoh K; Yamagata K; Koyama A
J Nephrol; 2005; 18(3):249-56. PubMed ID: 16013011
[TBL] [Abstract][Full Text] [Related]
13. Carboxy-terminal residues of major histocompatibility complex class II-associated peptides control the presentation of the bacterial superantigen toxic shock syndrome toxin-1 to T cells.
Wen R; Broussard DR; Surman S; Hogg TL; Blackman MA; Woodland DL
Eur J Immunol; 1997 Mar; 27(3):772-81. PubMed ID: 9079821
[TBL] [Abstract][Full Text] [Related]
14. Preparation of murine B7.1-glycosylphosphatidylinositol and transmembrane-anchored staphylococcal enterotoxin. A dual-anchored tumor cell vaccine and its antitumor effect.
Yi P; Yu H; Ma W; Wang Q; Minev BR
Cancer; 2005 Apr; 103(7):1519-28. PubMed ID: 15739200
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1.
Acharya KR; Passalacqua EF; Jones EY; Harlos K; Stuart DI; Brehm RD; Tranter HS
Nature; 1994 Jan; 367(6458):94-7. PubMed ID: 8107781
[TBL] [Abstract][Full Text] [Related]
16. The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen.
Hess AD; Thoburn C; Chen W; Miura Y; Van der Wall E
Clin Immunol; 2001 Oct; 101(1):67-76. PubMed ID: 11580228
[TBL] [Abstract][Full Text] [Related]
17. Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury.
Brogan PA; Shah V; Klein N; Dillon MJ
Arthritis Rheum; 2004 Feb; 50(2):589-97. PubMed ID: 14872503
[TBL] [Abstract][Full Text] [Related]
18. Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection.
Cui JC; Hu DL; Lin YC; Qian AD; Nakane A
FEMS Immunol Med Microbiol; 2005 Jul; 45(1):45-51. PubMed ID: 15985222
[TBL] [Abstract][Full Text] [Related]
19. Activation of T cells by superantigen in class II-negative mice.
Avery AC; Markowitz JS; Grusby MJ; Glimcher LH; Cantor H
J Immunol; 1994 Dec; 153(11):4853-61. PubMed ID: 7963549
[TBL] [Abstract][Full Text] [Related]
20. Engagement of MHC-class II molecules by staphylococcal exotoxins delivers a comitogenic signal to human B cells.
Fuleihan R; Mourad W; Geha RS; Chatila T
J Immunol; 1991 Mar; 146(5):1661-6. PubMed ID: 1847171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
